Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients

• Autori principali: Hana Votavova (Autore), Zuzana Urbanova (Autore), David Kundrat (Autore), Michaela Dostalova Merkerova (Autore), Martin Vostry (Autore), Monika Hruba (Autore), Jaroslav Cermak (Autore), Monika Belickova (Autore)
• Natura: Libro
• Pubblicazione: MDPI AG, 2021-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS p...